Novo Nordisk said Monday that it had entered into a license agreement with a Chinese company developing a competitor to ...

Novo Nordisk on Monday announced a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

Danish company Novo Nordisk's membership in a UK pharmaceutical industry body has been restored after a two-year suspension ...

Novo Nordisk A/S agreed to pay United Laboratories International Holdings as much as $2 billion for a next-generation obesity ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Novo Nordisk A/S (NYSE:NVO) returned to full membership of the Association of the British Pharmaceutical Industry (ABPI) ...

Eli Lilly says it is a first-of-its-kind treatment for obesity, overweight, and type 2 diabetes that activates both GIP and ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...

Student scientists have developed an incredible new way to synthesize drugs on plants — and they're using Ozempic as their ...